New research demonstrates the emerging
applications of Foundation Medicine’s liquid biopsy and monitoring
portfolio
Additional research investigates new biomarkers
and highlights the expanding utility of comprehensive genomic
profiling (CGP), including RNA sequencing
Foundation Medicine, Inc., today announced that 22 new pieces of
research from its robust oncology diagnostics portfolio will be
presented at the 2024 American Society of Clinical Oncology (ASCO)
Annual Meeting from May 31 to June 4 in Chicago.
Emerging Applications of Liquid Biopsy Using
FoundationOne®Liquid CDx and FoundationOne®Tracker
- Utility of circulating tumor DNA (ctDNA) to inform treatment of
patients with metastatic breast cancer (Abstract #1042)
- Use of circulating tumor DNA (ctDNA) to affect the adjuvant or
post-adjuvant treatment of patients with stage III and high-risk
stage II resected colon cancer: The ERASE-CRC project by GONO
(Abstract #TPS3644)
- Utility of ctDNA burden as a prognostic biomarker for efficacy
in TALAPRO-2: A phase 3 study of talazoparib (TALA) + enzalutamide
(ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in
patients (pts) with metastatic castration-resistant prostate cancer
(mCRPC) (Abstract #5020)
- Prognostic value of baseline circulating tumor DNA (ctDNA)
tumor fraction (TF) in metastatic hormone-sensitive prostate cancer
(mHSPC) (Abstract #5085)
- BRCA1/2 reversion mutations (BRCArev) in advanced prostate
cancer in the absence of prior PARP inhibitor (PARPi) therapy
(Abstract #5056)
Utility of CGP in Earlier Stages of Disease, Rare Cancers,
and Using RNA Sequencing
- Preliminary results of the Lung Cancer Mutation Consortium
LCMC4 evaluation of actionable drivers in early-stage lung cancer
(LEADER) screening trial (Abstract #8068)
- Impact of alterations in tumor suppressor genes (TSG-alt) on
survival outcomes in patients (pts) with de novo metastatic
castration-sensitive prostate cancer (dn-mCSPC) receiving androgen
deprivation therapy (ADT) with androgen receptor pathway inhibition
(ARPI) or docetaxel (Abstract #5091)
- On the right TRACK: Providing comprehensive genomic profiling
(CGP) and molecular tumor board (MTB) for patients (pts) with rare
cancers (Abstract #3127)
- New soft tissue sarcoma (STS) transcriptomic clusters to unveil
STS subsets with unique biological characteristics and refine the
accuracy of overall survival (OS) prediction (Abstract #11545)
New CGP Biomarkers, Including Homologous Recombination
Deficiency (HRD) Signature and Methyl Thioadenosine Phosphorylase
(MTAP) Genomic Loss
- Pathological complete response (pCR) association with a novel
homologous recombination deficiency HRD signature (HRDsig) in
patients with triple-negative breast cancer (TNBC) receiving
neoadjuvant therapy (Tx) (Abstract #591)
- Characterization of diverse targetable ERBB2 alterations in
512,993 patients with solid tumors (Abstract #3129)
- Nature and distribution of methyl thioadenosine phosphorylase
(MTAP) genomic loss in human tumors (Abstract #3067)
- Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in
HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC):
Co-occurrence and prevalence along treatment course (Abstract
#1060)
Impact of Ancestry on the Genomic Alteration
Landscape
- Genetic ancestry-associated differences in genomic profiling
and treatment patterns in pancreatic ductal adenocarcinoma (PDAC)
(Abstract #4138)
- Endometrial cancer (EC) by ERBB2 amplification (ERBB2amp)
status: Differences in molecular subtypes, ancestry, and real-world
outcomes (Abstract #5614)
“Our data at this year’s ASCO annual meeting reflects Foundation
Medicine’s progress in making genomic profiling indispensable to
cancer care and research, particularly in lung, breast and prostate
cancers where there is an increasing number of targeted therapies
for health care providers to consider for these patients,” says Mia
Levy, MD, PhD, Chief Medical Officer at Foundation Medicine. “We
are also excited to demonstrate our new RNA sequencing capabilities
and spotlight the expanding utility of ctDNA to inform treatment
decision making through a simple blood sample.”
The following is a complete list of Foundation Medicine
abstracts that will be presented. To access the abstracts being
presented at ASCO, please visit ASCO.org/abstracts.
Follow Foundation Medicine on LinkedIn, X and Instagram for more
updates from #ASCO24 and visit us in person at Booth #22031.
Abstract #
Title
Collaborator
Products
Posters
Abstract #3127 6/1/2024 9:00 AM- 12:00
PM
On the right TRACK: Providing
comprehensive genomic profiling (CGP) and molecular tumor board
(MTB) for patients (pts) with rare cancers
TargetCancer Foundation, UC San Diego
Moores Cancer Center, University of California, San Diego, Medical
College of Wisconsin (MCW) Cancer Center, The Sidney Kimmel
Comprehensive Cancer Center at The Johns Hopkins Hospital, The
University of Texas MD Anderson Cancer Center, Department of
Pharmacy, Rutgers New Jersey Medical School, Medication
Acquisition, Inc., Sarah Cannon Research Institute, University of
Nebraska, WIN Consortium for Precision Medicine
FoundationOne®CDx
FoundationOne®Liquid CDx
Abstract #3129 6/1/2024 9:00 AM- 12:00 PM
CDT
Characterization of diverse targetable
ERBB2 alterations in 512,993 patients with solid tumors
Memorial Sloan Kettering Cancer Center
FoundationOne®CDx
FoundationOne®Liquid CDx
Abstract #4138 6/1/2024 1:30 PM- 4:30 PM
CDT
Genetic ancestry-associated differences in
genomic profiling and treatment patterns in pancreatic ductal
adenocarcinoma (PDAC)
Yale Cancer Center, New York University
Perlmutter Cancer Center
FoundationOne®CDx Flatiron
Health-Foundation Medicine Clinico-Genomic Database (CGDB)
Abstract #TPS3644 6/1/2024 1:30 PM- 4:30
PM CDT
Use of circulating tumor DNA (ctDNA) to
affect the adjuvant or post-adjuvant treatment of patients with
stage III and high-risk stage II resected colon cancer: The
ERASE-CRC project by GONO
University of Pisa, Italy
FoundationOne®Tracker
Abstract #11545 6/1/2024 1:30 PM- 4:30 PM
CDT
New soft tissue sarcoma (STS)
transcriptomic clusters to unveil STS subsets with unique
biological characteristics and refine the accuracy of overall
survival (OS) prediction
Universitario Lisboa Norte, Institute
Portugues de Oncologia de Lisboa Francisco Gentil, Institute
Superior Tecnico, Universidade de Lisboa, Institute de Medicina
Molecular Joao Lobo Antunes, Faculdade de Medicina da Universidade
de Lisboa, F. Hoffmann-La Roche AG, Institute Superior Tecnico
(1ST), Universidade de Lisboa, Hospital CUF Descobertas
FoundationOne®RNA for research
use
Abstract #3067
6/1/2024 9:00 AM- 12:00 PM CDT
Nature and distribution of methyl
thioadenosine phosphorylase (MTAP) genomic loss in human tumors
San Raffaele Hospital and Scientific
Institute, Italy
FoundationOne®
FoundationOne®CDx
Abstract #1060 6/2/2024 9:00 AM- 12:00 PM
CDT
Genomic alterations (GA) in ESR1, PIK3CA,
AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic
breast cancer (MBC): co-occurrence and prevalence along treatment
course
Emory University
FoundationOne®CDx
FoundationOne®Liquid CDx Flatiron Health-Foundation Medicine
Clinico-Genomic Database (CGDB)
Abstract #591 6/2/2024 9:00 AM- 12:00 PM
CDT
Pathological complete response (pCR)
association with a novel homologous recombination deficiency HRD
signature (HRDsig) in patients with triple-negative breast cancer
(TNBC) receiving neoadjuvant therapy (Tx)
Stanford University
FoundationOne®CDx Flatiron
Health-Foundation Medicine Clinico-Genomic Database (CGDB)
Abstract #5056 6/2/2024 9:00 AM- 12:00 PM
CDT
BRCA1/2 reversion mutations in advanced
prostate cancer in the absence of prior PARP inhibitor (PARPi)
therapy
Cedars-Sinai Medical Center, Upstate
University Medical Center, University of California - San Diego
FoundationOne®Liquid CDx
Abstract #1042 6/2/2024 9:00 AM- 12:00 PM
CDT
Utility of circulating tumor DNA (ctDNA)
to inform treatment of patients with metastatic breast cancer
Johns Hopkins University School of
Medicine, Vanderbilt University Medical Center, Allegheny Health
Network, Weill Cornell Medicine and New York-Presbyterian
Hospital
FoundationOne®Liquid CDx
Abstract #5091 6/2/2024 9:00 AM- 12:00 PM
CDT
Impact of alterations in tumor suppressor
genes (TSG-alt) on survival outcomes in patients (pts) with de novo
metastatic castration-sensitive prostate cancer (dn-mCSPC)
receiving androgen deprivation therapy (ADT) with androgen receptor
pathway inhibition (ARPI) or docetaxel
Huntsman Cancer Institute, Masonic Cancer
Center
Flatiron Health-Foundation Medicine
Clinico-Genomic Database (CGDB)
Abstract #5085 6/2/2024 9:00 AM- 12:00 PM
CDT
Prognostic value of baseline circulating
tumor DNA (ctDNA) tumor fraction (TF) in metastatic
hormone-sensitive prostate cancer (mHSPC)
Rogel Comprehensive Cancer Center,
University of Michigan, Karmanos Cancer Institute, Wayne State
University
FoundationOne®Liquid CDx
Abstract #5020 6/2/2024 9:00 AM- 12:00 PM
CDT
Utility of ctDNA burden as a prognostic
biomarker for efficacy in TALAPRO-2: A phase 3 study of talazoparib
(TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line
(1L) treatment in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC)
Peter MacCallum Cancer Centre, Department
of Medical Oncology, Institut Gustave Roussy, University of
Paris-Saclay, Pfizer Inc., National Cancer Center Hospital East,
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino
Amadori, Department of Oncology, University of Turin, San Luigi
Gonzaga Hospital, Orbassano, The Urology Center of Colorado,
National Cancer Center, Tom Baker Cancer Centre, University of
Calgary, National Center for Tumor Diseases (NCT), Heidelberg
University Hospital, Huntsman Cancer Institute (NCI-CCC),
University of Utah
FoundationOne®Liquid CDx
FoundationOne®Monitor for Research Use
Abstract #3626 6/2/2024 9:00 AM- 12:00 PM
CDT
Contrasting comprehensive genomic profiles
of adenocarcinomas of the appendix in younger versus older
patients
Upstate Medical University
FoundationOne®
FoundationOne®CDx
Abstract #4588 6/2/2024 9:00 AM- 12:00 PM
CDT
FGFR3-mutated urothelial carcinoma of
bladder and upper tract including ureter and renal pelvis: A
comparative genomic profiling study
Upstate Medical University, University of
California – Los Angeles, University of Washington, Huntsman Cancer
Center, Moffitt Cancer Center, MD Anderson Cancer Center, Cleveland
Clinic, San Rafael University
FoundationOne®
FoundationOne®CDx
Abstract #8032 6/2/2024 9:00 AM- 12:00 PM
CDT
Retrospective analysis of change in
frequency of STK11 mutation in lung adenocarcinomas over a 10-year
period
Upstate Medical University
FoundationOne®
FoundationOne®CDx
Abstract #1092 6/2/2024 9:00 AM- 12:00 PM
CDT
Impact of HER2 low status on genomic
signatures in triple negative breast cancer (TNBC)
Yale University
FoundationOne®
FoundationOne®CDx
Abstract #11575 6/2/2024 9:00 AM- 12:00 PM
CDT
Intimal sarcomas (ISarc) of the cardiac
chambers (CC) of the heart and great vessels (GV): A comprehensive
genomic profiling (CGP) study
Upstate Medical University
FoundationOne®
FoundationOne®CDx
Abstract #6036 6/2/2024 9:00 AM- 12:00 PM
CDT
Clinical, molecular, and immunologic
profiling of brain metastases (BM) in head and neck squamous cell
carcinoma (HNSCC)
Dana-Farber Cancer Institute, University
of California – San Diego, Phase Genomics
Abstract #5614 6/3/2024 9:00 AM- 12:00 PM
CDT
Endometrial cancer (EC) by ERBB2
amplification (ERBB2amp) status: Differences in molecular subtypes,
ancestry, and real-world outcomes
University of Colorado Health, Mount
Sinai
FoundationOne®CDx
Abstract #8068 6/3/2024 1:30 PM- 4:30 PM
CDT
Preliminary results of the Lung Cancer
Mutation Consortium LCMC4 evaluation of actionable drivers in
early-stage lung cancer (LEADER) screening trial
Baylor College of Medicine, Harvard
University, University of Michigan, University of Missouri,
University of Washington, University of California – Los Angeles,
University of Colorado, Memorial Sloan Kettering
FoundationOne®CDx
FoundationOne®Liquid CDx
Abstract #8532 6/3/2024 1:30 PM- 4:30 PM
CDT
Molecular profiling across histologies in
lung cancer: Time to change WHO nomenclature?
Tisch Cancer Institute, Icahn School of
Medicine at Mount Sinai, Papardo Hospital, Roche Sequencing
Solutions
FoundationOne®CDx
Foundation Medicine® and FoundationOne® are registered
trademarks of Foundation Medicine, Inc.
About Foundation Medicine: Your Essential Partner in Cancer
Care
Foundation Medicine is a pioneer in molecular profiling for
cancer, working to shape the future of clinical care and research.
We collaborate with a broad range of partners across the cancer
community and strive to set the standard for quality, scientific
excellence, and regulatory leadership. Our deep understanding of
cancer biology helps physicians make informed treatment decisions
for their patients and empowers researchers to develop new
medicines. Every day, we are driven to help our partners find
answers and take action, enabling more people around the world to
benefit from precision cancer care. For more information, please
visit us on www.FoundationMedicine.com and follow us on LinkedIn
and X.
About FoundationOne®CDx
FoundationOne®CDx is a next-generation sequencing based
in vitro diagnostic device for detection of substitutions,
insertion and deletion alterations (indels), and copy number
alterations (CNAs) in 324 genes and select gene rearrangements, as
well as genomic signatures including microsatellite instability
(MSI) and tumor mutational burden (TMB) using DNA isolated from
formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens.
FoundationOne CDx is for prescription use only and is intended as a
companion diagnostic to identify patients who may benefit from
treatment with certain targeted therapies in accordance with their
approved therapeutic product labeling. Additionally, FoundationOne
CDx is intended to provide tumor mutation profiling to be used by
qualified health care professionals in accordance with professional
guidelines in oncology for patients with solid malignant neoplasms.
Use of the test does not guarantee a patient will be matched to a
treatment. A negative result does not rule out the presence of an
alteration. Some patients may require a biopsy. For a full list of
targeted therapies for which FoundationOne CDx is indicated as a
companion diagnostic, please visit www.F1CDxLabel.com.
About FoundationOne®Liquid CDx
FoundationOne®Liquid CDx is a qualitative next generation
sequencing based in vitro diagnostic test for prescription use only
that uses targeted high throughput hybridization-based capture
technology to analyze 324 genes utilizing circulating cell-free DNA
(cfDNA) isolated from plasma derived from anti-coagulated
peripheral whole blood of advanced cancer patients. The test is
FDA-approved to report short variants in over 300 genes and is a
companion diagnostic to identify patients who may benefit from
treatment with specific therapies (listed in Table 1 of the
Intended Use) in accordance with the approved therapeutic product
labeling. Additional genomic findings may be reported and are not
prescriptive or conclusive for labeled use of any specific
therapeutic product. Use of the test does not guarantee a patient
will be matched to a treatment. A negative result does not rule out
the presence of an alteration. Patients who are negative for
companion diagnostic mutations should be reflexed to tumor tissue
testing and mutation status confirmed using an FDA-approved tumor
tissue test, if feasible. For the complete label, including
companion diagnostic indications and complete risk information,
please visit www.F1LCDxLabel.com.
About FoundationOne®Tracker
FoundationOne®Tracker is a personalized assay for oncology that
is based on patient-specific somatic variants (substitutions and
short insertions/deletions) identified from baseline tumor tissue
testing and used to detect and longitudinally measure plasma
circulating tumor DNA (ctDNA) abundance as a biomarker for tumor
burden. FoundationOne Tracker is performed exclusively as a
laboratory service and has not been cleared or approved by the U.S.
Food and Drug Administration. For technical specifications, please
visit FoundationMedicine.com.
About FoundationOne®RNA
FoundationOne®RNA is a laboratory developed test that was
developed and its performance characteristics determined by
Foundation Medicine. FoundationOne RNA has not been cleared or
approved by the U.S. Food and Drug Administration. FoundationOne
RNA is a test for solid tumors which utilizes RNA sequencing to
interrogate 318 cancer-related genes to capture gene fusions and
rearrangements. A negative result does not rule out the presence of
an alteration. Genomic findings are not prescriptive or conclusive
for labeled use of any specific therapeutic product.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240524219879/en/
Holly Campbell, 480-213-8368 newsroom@foundationmedicine.com